Tumoricidal and antimicrobial compositions and methods
Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
1. A method for treating a tumor in a patient comprising administering an effective amount of the pharmaceutical composition to the patient so as to treat the tumor, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and one or more isolated components from NK-92 cells, wherein the one or more components comprise exosomes and/or microvesicles and are tumoricidal.
2. The method of claim 1 , wherein the pharmaceutical composition comprises a sterile aqueous solution.
3. The method of claim 2 , wherein the sterile aqueous composition comprises a supernatant of a medium of NK-92 cells.
4. The method of claim 1 , wherein the administering the pharmaceutical composition is by injection.
5. The method of claim 4 , wherein the administering the pharmaceutical composition is by subdermal or subcutaneous injection.
6. The method of claim 1 , wherein the pharmaceutical composition is an injectable extended release formulation.
7. The method of claim 1 , wherein the pharmaceutical composition is a topical formulation.
8. The method of claim 7 , wherein the topical formulation is liquid at room temperature and becomes a gel when applied to the body.
9. The method of claim 8 , wherein the topical formulation comprises a poloxamer.
10. The method of claim 7 , wherein the pharmaceutical composition is a cream or lotion.
11. The method of claim 1 , wherein the NK-92 cells comprise wild type NK-92 cells.
12. The method of claim 1 , wherein the NK-92 cells comprise modified NK-92 cells.
13. The method of claim 12 , wherein the modified NK-92 cells express an Fc receptor, a cytokine, a cytokine receptor and/or a chimeric antigen receptor.
14. The method of claim 1 , wherein the pharmaceutical acceptable carrier comprises a thickening agent.
15. The method of claim 1 , wherein the pharmaceutical composition further comprises one or more cytokines.
16. The method of claim 15 , wherein the one or more cytokines include at least IL-2.
17. The method of claim 1 , wherein the one or more NK-92 cells are treated with at least one stimulatory agent prior to isolation of the one or more components.
18. The method of claim 17 , wherein the at least one stimulatory agent is IL-15 and/or interferon gamma.